Results 81 to 90 of about 31,702 (234)
Gait Pattern at Different Speeds in Persons With Haemophilia
Haemophilia, EarlyView.ABSTRACT Introduction Persons with haemophilia (PwH) have a risk of bleeding in joints, especially in elbow, knee and ankle. In the long term, this leads to haemophilic arthropathy (HA), which results in joint deformities. Aim This study aims to examine how walking speed and HA affect (1) foot pressure distribution, (2) average vertical peak pressure ...
Marius Brühl +8 more
wiley +1 more source
Beyond Standard Half‐Life: Real‐world Pharmacokinetics of Efanesoctocog Alfa in a Single Centre
Haemophilia, EarlyView.ABSTRACT Introduction Efanesoctocog alfa (EFA) is an ultra–extended half‐life factor VIII (FVIII) developed to address limitations of conventional prophylaxis in haemophilia A. Although the XTEND trials reported low interindividual pharmacokinetic (PK) variability, real‐world data remain important to better characterize PK profiles across patient ...
Laurent Sattler +6 more
wiley +1 more source
Hematology, 2006 Acquired hemophilia A is a rare but severe autoimmune bleeding disorder, resulting from the presence of autoantibodies directed against clotting factor VIII. The etiology of the disorder remains obscure, although approximately half of all cases are associated with other underlying conditions.
openaire +2 more sources
UK Infected Blood Inquiry–An Historical Appraisal
Haemophilia, EarlyView.ABSTRACT Introduction This appraisal considers the 2018 UK Infected Blood Inquiry and its Report (2024) in the context of the history of haemophilia treatment developments over the past fifty‐five years, and the tragic impacts of the AIDS pandemic. Aim The paper appraises the conduct and findings of the IBI and its Report in relation to HIV and AIDS ...
Christopher A. Ludlam
wiley +1 more source
Haemophilia, EarlyView.ABSTRACT Introduction Performance‐based measures are essential for detecting early musculoskeletal functional limitations in patients with haemophilia (PwH). The Weight‐Bearing Lunge Test (WBLT) assesses ankle dorsiflexion mobility, but its psychometric properties in PwH remain unclear.
Firat Tan +3 more
wiley +1 more source
Emicizumab in the treatment of acquired hemophilia A: A Two-Center experience
Annals of HematologyEmicizumab is a FVIII mimetic antibody used in the treatment of inherited hemophilia A that could potentially be used in acquired hemophilia A (AHA) to achieve hemostasis and shorten hospital stay while reducing bypass therapies. We report on 12 cases of
Malcolm Su +3 more
doaj +1 more source
Haemophilia, EarlyView.ABSTRACT Introduction Prophylactic factor replacement and non‐factor therapy has improved bleed prevention and clinical outcomes for people with haemophilia (PwH). The remaining burdens faced by PwH in real‐world settings, despite availability of newer therapies, are not well documented.
Víctor Jiménez Yuste +5 more
wiley +1 more source
Defining the Role of Nurses in Gene Therapy for Haemophilia
Haemophilia, EarlyView.Abstract Introduction Haemophilia is a rare bleeding disorder now undergoing a major shift in care as gene therapy (GT), delivered through viral‑vector in vivo gene transfer, has enabled adults with haemophilia A or B to stop prophylaxis with minimal bleeding.
Greta Mulders +5 more
wiley +1 more source
Haemophilia, EarlyView.ABSTRACT Background Despite effective bleed prevention with Emicizumab, pain remains a relevant clinical burden in adults with severe haemophilia A (sHA). A multidimensional assessment is needed to better characterize contemporary haemophilia‐related pain.
Ilenia Lorenza Calcaterra +7 more
wiley +1 more source